CMV Tonsillitis Treatment Approach

Primary Recommendations

The Centers for Disease Control and Prevention recommends initiating intravenous ganciclovir 5 mg/kg twice daily immediately for CMV tonsillitis in immunocompromised patients, transitioning to oral valganciclovir 900 mg twice daily after 3-5 days if symptoms improve and oral absorption is adequate, continuing treatment for 21-28 days or until symptoms resolve 1, 2, 3
Immediate antiviral therapy is mandatory for immunocompromised patients as CMV tonsillitis represents mucosal CMV disease requiring systemic treatment similar to CMV esophagitis 1, 2

For immunocompromised patients, start IV ganciclovir 5 mg/kg twice daily for initial 3-5 days to rapidly achieve therapeutic drug levels, then transition to oral valganciclovir 900 mg twice daily after clinical improvement is observed and gastrointestinal absorption is assured 3, 4
Continue treatment for 21-28 days total or until complete resolution of signs and symptoms 1, 2, 5

Tissue biopsy with histopathology showing characteristic CMV intranuclear and intracytoplasmic inclusions is the gold standard for mucosal CMV disease 2, 7
CMV PCR from throat swab or biopsy can support diagnosis but positive viral culture alone is insufficient in immunocompromised patients who may have asymptomatic viral shedding 2, 7

For HIV-infected patients, initiate or optimize antiretroviral therapy concurrently with CMV treatment, and continue CMV therapy until immune recovery (CD4+ count >100 cells/µL sustained for 3-6 months) 1, 5, 3
For transplant or other immunosuppressed patients, reduce immunosuppression if clinically feasible, and monitor CMV viral load weekly by PCR to assess treatment response 3, 6

Twice-weekly monitoring during induction phase (first 3-5 days) should include complete blood count, serum creatinine and electrolytes, and clinical symptom assessment 1, 5, 6
Weekly monitoring during maintenance phase should include complete blood count, renal function, CMV viral load by PCR, and clinical response 1, 5, 4

Ganciclovir/Valganciclovir can cause neutropenia and thrombocytopenia (most common, dose-limiting), nausea and diarrhea, and renal dysfunction 1, 5, 3
Foscarnet (if used as alternative) can cause nephrotoxicity, electrolyte abnormalities, and neurologic dysfunction including seizures 3, 6